PriceTargets.com logo

Abbott Laboratories - ABT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $147.00
  • Forecasted Upside: 17.23%
  • Number of Analysts: 23
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 17 Buy Ratings
  • 2 Strong Buy Ratings
$125.39 As of 12/4/2025 04:59 PM ET
▲ +0.1 (0.08%)

This chart shows the closing price for ABT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Abbott Laboratories Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABT

Analyst Price Target is $147.00
▲ +17.23% Upside Potential
This price target is based on 23 analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is $147.00, with a high forecast of $162.00 and a low forecast of $136.00. The average price target represents a 17.23% upside from the last price of $125.39.

This chart shows the closing price for ABT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 23 contributing investment analysts is to moderate buy stock in Abbott Laboratories. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 14 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 2 strong buy ratings
  • 16 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 2 strong buy ratings
  • 17 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 2 strong buy ratings
  • 17 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 2 strong buy ratings
  • 17 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/20/2025William BlairUpgradeStrong-Buy
11/20/2025BTIG ResearchReiterated RatingBuy ➝ Buy$145.00
10/21/2025Daiwa Capital MarketsBoost TargetOutperform ➝ Outperform$134.00 ➝ $136.00
10/17/2025BarclaysBoost TargetOverweight ➝ Overweight$159.00 ➝ $162.00
10/16/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$142.00 ➝ $146.00
10/16/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$147.00
10/16/2025Raymond James FinancialBoost TargetOutperform ➝ Outperform$141.00 ➝ $146.00
10/16/2025Sanford C. BernsteinBoost TargetOutperform ➝ Outperform$145.00 ➝ $150.00
10/16/2025Jefferies Financial GroupBoost TargetBuy ➝ Buy$145.00 ➝ $149.00
10/15/2025Evercore ISILower TargetOutperform ➝ Outperform$144.00 ➝ $142.00
10/15/2025BTIG ResearchReiterated RatingBuy ➝ Buy$145.00
10/14/2025MizuhoBoost TargetNeutral ➝ Neutral$135.00 ➝ $140.00
10/10/2025BenchmarkInitiated CoverageBuy$145.00
10/8/2025Weiss RatingsReiterated RatingBuy (B) ➝ Buy (B)
10/7/2025Evercore ISIBoost TargetOutperform ➝ Outperform$140.00 ➝ $144.00
10/1/2025The Goldman Sachs GroupBoost TargetBuy ➝ Buy$153.00 ➝ $157.00
9/27/2025Weiss RatingsReiterated RatingBuy (B) ➝ Buy (B)
7/18/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$147.00 ➝ $142.00
7/18/2025Raymond James FinancialLower TargetOutperform ➝ Outperform$142.00 ➝ $141.00
7/18/2025BTIG ResearchLower TargetBuy ➝ Buy$148.00 ➝ $145.00
7/18/2025Jefferies Financial GroupUpgradeHold ➝ Buy$143.00 ➝ $145.00
7/17/2025William BlairUpgradeStrong-Buy
7/16/2025MizuhoBoost TargetNeutral ➝ Neutral$130.00 ➝ $140.00
7/15/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$145.00 ➝ $147.00
7/15/2025Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$127.00 ➝ $137.00
7/8/2025Evercore ISIBoost TargetOutperform ➝ Outperform$140.00 ➝ $145.00
6/16/2025Leerink PartnrsUpgradeHold
6/16/2025Leerink PartnersInitiated CoverageMarket Perform$143.00
4/17/2025Piper SandlerReiterated RatingOverweight ➝ Overweight$133.00 ➝ $145.00
4/17/2025Raymond James FinancialBoost TargetOutperform ➝ Outperform$132.00 ➝ $142.00
4/17/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$140.00 ➝ $145.00
4/17/2025Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$117.00 ➝ $127.00
4/17/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$136.00 ➝ $147.00
4/17/2025BarclaysBoost TargetOverweight ➝ Overweight$158.00 ➝ $159.00
4/17/2025Stifel NicolausBoost TargetBuy ➝ Buy$135.00 ➝ $145.00
4/17/2025Jefferies Financial GroupBoost TargetHold ➝ Hold$135.00 ➝ $137.00
3/10/2025Bank of AmericaBoost TargetBuy ➝ Buy$133.00 ➝ $150.00
3/4/2025CitigroupBoost TargetBuy ➝ Buy$135.00 ➝ $160.00
3/4/2025The Goldman Sachs GroupBoost TargetBuy ➝ Buy$138.00 ➝ $154.00
1/28/2025ArgusUpgradeStrong-Buy
1/27/2025BarclaysReiterated RatingOverweight ➝ Overweight$149.00 ➝ $158.00
1/23/2025Stifel NicolausBoost TargetBuy ➝ Buy$130.00 ➝ $135.00
1/23/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$133.00 ➝ $136.00
1/23/2025UBS GroupBoost TargetBuy ➝ Buy$146.00 ➝ $148.00
1/21/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$135.00 ➝ $135.00
1/2/2025Evercore ISIBoost TargetBuy$136.00
11/5/2024BarclaysBoost TargetOverweight ➝ Overweight$143.00 ➝ $149.00
10/17/2024Sanford C. BernsteinBoost TargetOutperform ➝ Outperform$133.00 ➝ $138.00
10/17/2024UBS GroupBoost TargetBuy ➝ Buy$143.00 ➝ $146.00
10/17/2024Jefferies Financial GroupBoost TargetHold ➝ Hold$120.00 ➝ $125.00
10/17/2024MizuhoBoost TargetNeutral ➝ Neutral$115.00 ➝ $130.00
10/17/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$107.00 ➝ $117.00
10/17/2024Piper SandlerBoost TargetOverweight ➝ Overweight$131.00 ➝ $133.00
10/14/2024Raymond James FinancialReiterated RatingOutperform ➝ Buy$122.00 ➝ $129.00
10/8/2024Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$125.00 ➝ $130.00
10/8/2024OppenheimerInitiated CoverageOutperform$130.00
10/1/2024Evercore ISIBoost TargetOutperform ➝ Outperform$120.00 ➝ $124.00
9/26/2024Jefferies Financial GroupReiterated RatingHold ➝ Hold$120.00 ➝ $120.00
9/19/2024Piper Sandler CompaniesInitiated CoverageOverweight$131.00
9/19/2024Piper SandlerInitiated CoverageOverweight$131.00
8/22/2024CitigroupBoost TargetBuy ➝ Buy$119.00 ➝ $127.00
7/30/2024Edward JonesDowngradeBuy ➝ Hold
7/29/2024BarclaysBoost TargetOverweight ➝ Overweight$140.00 ➝ $143.00
7/2/2024Evercore ISILower TargetOutperform ➝ Outperform$125.00 ➝ $120.00
6/4/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$125.00 ➝ $125.00
5/30/2024The Goldman Sachs GroupInitiated CoverageBuy$121.00
5/22/2024CitigroupLower TargetBuy ➝ Buy$128.00 ➝ $119.00
4/24/2024Raymond James FinancialReiterated RatingBuy$124.00
4/22/2024BarclaysLower TargetOverweight ➝ Overweight$141.00 ➝ $140.00
4/18/2024Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$128.00 ➝ $125.00
4/4/2024Evercore ISIBoost TargetOutperform ➝ Outperform$120.00 ➝ $125.00
4/3/2024CitigroupBoost TargetBuy ➝ Buy$126.00 ➝ $128.00
2/14/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$128.00
1/26/2024BarclaysBoost TargetOverweight ➝ Overweight$133.00 ➝ $141.00
1/25/2024CitigroupBoost TargetBuy ➝ Buy$123.00 ➝ $126.00
1/25/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$128.00
1/25/2024Raymond James FinancialBoost TargetOutperform ➝ Outperform$124.00 ➝ $127.00
1/11/2024Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$119.00 ➝ $128.00
1/3/2024Raymond James FinancialBoost TargetOutperform ➝ Outperform$110.00 ➝ $124.00
12/13/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$116.00 ➝ $121.00
10/19/2023UBS GroupLower Target$130.00 ➝ $118.00
10/19/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$112.00 ➝ $107.00
10/19/2023Raymond James FinancialLower TargetOutperform ➝ Outperform$123.00 ➝ $110.00
10/19/2023Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$136.00 ➝ $116.00
10/2/2023Jefferies Financial GroupLower Target$120.00 ➝ $112.00
10/2/2023CitigroupLower Target$130.00 ➝ $122.00
7/24/2023BarclaysBoost TargetOverweight$127.00 ➝ $132.00
7/21/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$112.00
7/21/2023MizuhoBoost TargetNeutral ➝ Neutral$110.00 ➝ $115.00
7/21/2023Wolfe ResearchUpgradeUnderperform ➝ Peer Perform
5/30/2023Morgan StanleyDowngradeOverweight ➝ Equal Weight$112.00
4/20/2023Raymond James FinancialBoost Target$116.00 ➝ $123.00
4/20/2023Wolfe ResearchLower TargetUnderperform$107.00 ➝ $103.00
4/20/2023Sanford C. BernsteinBoost TargetOutperform$132.00 ➝ $133.00
4/20/2023JPMorgan Chase & Co.Boost TargetOverweight$118.00 ➝ $122.00
4/20/2023UBS GroupBoost TargetBuy$117.00 ➝ $130.00
4/20/2023BarclaysBoost TargetOverweight$125.00 ➝ $127.00
4/19/2023CitigroupBoost TargetBuy$125.00 ➝ $130.00
4/17/2023BTIG ResearchBoost TargetBuy$125.00 ➝ $130.00
4/17/2023Raymond James FinancialLower TargetOutperform$123.00 ➝ $116.00
4/5/2023Wells Fargo & CompanyLower TargetOverweight$140.00 ➝ $136.00
3/31/2023Leerink PartnersBoost TargetMarket Perform$90.00 ➝ $102.00
3/30/2023Bank of AmericaLower Target$125.00 ➝ $115.00
3/28/2023UBS GroupInitiated CoverageBuy$117.00
1/27/2023BarclaysBoost TargetOverweight$122.00 ➝ $125.00
1/26/2023Stifel NicolausBoost TargetBuy$110.00 ➝ $125.00
1/26/2023Raymond James FinancialBoost TargetOutperform$109.00 ➝ $123.00
1/26/2023Sanford C. BernsteinBoost TargetOutperform$125.00 ➝ $132.00
1/24/2023MizuhoBoost TargetNeutral$105.00 ➝ $110.00
1/6/2023Morgan StanleyBoost TargetOverweight$117.00 ➝ $133.00
1/4/2023BarclaysBoost Target$114.00 ➝ $122.00
12/12/2022CitigroupBoost TargetBuy$114.00 ➝ $125.00
10/26/2022MizuhoInitiated CoverageNeutral$105.00
10/21/2022Raymond James FinancialLower TargetOutperform$117.00 ➝ $109.00
10/20/2022Evercore ISILower Target$110.00
10/20/2022Morgan StanleyLower TargetOverweight$126.00 ➝ $117.00
10/20/2022Royal Bank Of CanadaLower TargetOutperform$132.00 ➝ $126.00
10/17/2022BarclaysInitiated CoverageOverweight$118.00
10/17/2022BTIG ResearchLower TargetBuy$126.00 ➝ $123.00
10/12/2022Jefferies Financial GroupInitiated CoverageHold$110.00
10/11/2022Morgan StanleyLower TargetOverweight$132.00 ➝ $126.00
10/10/2022Wells Fargo & CompanyLower TargetOverweight$150.00 ➝ $140.00
10/5/2022CitigroupLower Target$123.00 ➝ $117.00
8/25/2022Erste Group BankDowngradeBuy ➝ Hold
7/27/2022UBS GroupLower TargetBuy$142.00 ➝ $128.00
7/22/2022Evercore ISILower Target$112.00
7/21/2022Morgan StanleyLower TargetOverweight$134.00 ➝ $132.00
7/21/2022Royal Bank Of CanadaLower Target$143.00 ➝ $132.00
7/21/2022CitigroupLower TargetBuy$125.00 ➝ $123.00
7/18/2022BTIG ResearchLower TargetBuy$130.00 ➝ $126.00
7/18/2022Stifel NicolausLower Target$136.00 ➝ $126.00
7/15/2022Morgan StanleyLower TargetOverweight$145.00 ➝ $134.00
7/13/2022CowenLower Target$150.00 ➝ $130.00
7/13/2022CowenLower Target$150.00 ➝ $130.00
7/5/2022Wolfe ResearchInitiated CoverageUnderperform
6/24/2022BTIG ResearchLower TargetBuy$140.00 ➝ $130.00
6/7/2022Morgan StanleyLower TargetOverweight$151.00 ➝ $145.00
5/17/2022CitigroupLower TargetNA$154.00 ➝ $125.00
4/21/2022Royal Bank Of CanadaLower TargetOutperform$146.00 ➝ $143.00
4/21/2022Raymond James FinancialLower TargetOutperform$143.00 ➝ $135.00
4/8/2022Wells Fargo & CompanyLower TargetOverweight$155.00 ➝ $150.00
3/1/2022Bank of AmericaInitiated CoverageBuy ➝ Buy$140.00
1/27/2022Credit Suisse GroupBoost TargetOutperform$138.00 ➝ $139.00
1/27/2022UBS GroupBoost TargetBuy ➝ Buy$138.00 ➝ $142.00
1/27/2022Morgan StanleyLower TargetOverweight$157.00 ➝ $151.00
1/27/2022Raymond James FinancialLower TargetOutperform$150.00 ➝ $143.00
1/26/2022BTIG ResearchLower Target$143.00 ➝ $138.00
1/10/2022CowenBoost Target$140.00 ➝ $150.00
1/7/2022Morgan StanleyBoost TargetOverweight$146.00 ➝ $157.00
12/23/2021Raymond James FinancialLower Target$150.00 ➝ $134.00
12/22/2021Raymond James FinancialBoost TargetOutperform$134.00 ➝ $150.00
12/9/2021Royal Bank Of CanadaInitiated CoverageOutperform$146.00
10/27/2021Atlantic SecuritiesUpgradeNeutral ➝ Overweight$144.00
10/21/2021Morgan StanleyBoost TargetOverweight$136.00 ➝ $146.00
10/21/2021Leerink PartnersReiterated RatingMarket Perform$128.00 ➝ $140.00
10/21/2021Raymond James FinancialBoost TargetPositive ➝ Outperform$128.00 ➝ $134.00
10/14/2021Redburn PartnersInitiated CoverageNeutral$103.13 ➝ $132.28
10/8/2021CowenReiterated RatingBuy$140.00
10/1/2021CitigroupBoost TargetBuy$135.00 ➝ $140.00
8/31/2021BTIG ResearchBoost TargetBuy$126.00 ➝ $136.00
8/23/2021CowenBoost TargetPositive ➝ Outperform$125.00 ➝ $140.00
7/23/2021Morgan StanleyBoost TargetOverweight$126.00 ➝ $136.00
7/23/2021Credit Suisse GroupBoost TargetOutperform$120.00 ➝ $130.00
7/23/2021Raymond James FinancialBoost TargetOutperform$116.00 ➝ $128.00
7/20/2021Leerink PartnersBoost TargetMarket Perform$115.00 ➝ $128.00
7/12/2021Wells Fargo & CompanyBoost TargetMarket Perform ➝ Overweight$125.00 ➝ $135.00
6/2/2021BTIG ResearchLower TargetBuy$140.00 ➝ $120.00
6/2/2021Credit Suisse GroupLower TargetOutperform$133.00 ➝ $120.00
6/2/2021BarclaysLower TargetOverweight$150.00 ➝ $125.00
6/2/2021Wells Fargo & CompanyLower TargetOverweight$137.00 ➝ $125.00
6/2/2021Raymond James FinancialLower TargetOutperform$130.00 ➝ $116.00
6/2/2021Morgan StanleyLower TargetOverweight$140.00 ➝ $126.00
6/2/2021CitigroupReiterated RatingBuy$138.00 ➝ $125.00
5/24/2021BarclaysInitiated CoverageOverweight$150.00
4/21/2021Morgan StanleyBoost TargetOverweight$136.00 ➝ $140.00
4/20/2021William BlairReiterated RatingOutperform
4/15/2021Atlantic SecuritiesInitiated CoverageNeutral$122.00
3/11/2021Raymond James FinancialBoost TargetOutperform$126.00 ➝ $130.00
1/28/2021Wells Fargo & CompanyBoost Target$128.00 ➝ $137.00
1/28/2021CowenBoost TargetOutperform$113.00 ➝ $140.00
1/28/2021Credit Suisse GroupBoost TargetOutperform$118.00 ➝ $130.00
1/28/2021Morgan StanleyBoost TargetOverweight$126.00 ➝ $136.00
1/28/2021Leerink PartnersBoost TargetMarket Perform$115.00 ➝ $128.00
1/28/2021Raymond James FinancialBoost TargetOutperform$114.00 ➝ $126.00
1/28/2021BTIG ResearchUpgradeNeutral ➝ Buy$140.00
12/15/2020Morgan StanleyBoost TargetOverweight$121.00 ➝ $126.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

1.41 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 182 very positive mentions
  • 43 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 210 very positive mentions
  • 26 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 210 very positive mentions
  • 26 positive mentions
  • 6 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Abbott Laboratories logo
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Read More

Today's Range

Now: $125.39
Low: $124.06
High: $125.57

50 Day Range

MA: $128.71
Low: $123.61
High: $134.49

52 Week Range

Now: $125.39
Low: $110.86
High: $141.23

Volume

5,226,853 shs

Average Volume

6,355,666 shs

Market Capitalization

$218.04 billion

P/E Ratio

15.71

Dividend Yield

1.88%

Beta

0.72

Frequently Asked Questions

What sell-side analysts currently cover shares of Abbott Laboratories?

The following sell-side analysts have issued reports on Abbott Laboratories in the last year: Argus, Bank of America Corporation, Barclays PLC, Benchmark Co., BTIG Research, Citigroup Inc., Daiwa Capital Markets, Evercore ISI, Jefferies Financial Group Inc., Leerink Partners, Leerink Partnrs, Mizuho, Morgan Stanley, Piper Sandler, Raymond James Financial, Inc., Royal Bank Of Canada, Sanford C. Bernstein, Stifel Nicolaus, The Goldman Sachs Group, Inc., UBS Group AG, Wall Street Zen, Weiss Ratings, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for ABT.

What is the current price target for Abbott Laboratories?

0 Wall Street analysts have set twelve-month price targets for Abbott Laboratories in the last year. Their average twelve-month price target is $147.00, suggesting a possible upside of 17.2%. Barclays PLC has the highest price target set, predicting ABT will reach $162.00 in the next twelve months. Daiwa Capital Markets has the lowest price target set, forecasting a price of $136.00 for Abbott Laboratories in the next year.
View the latest price targets for ABT.

What is the current consensus analyst rating for Abbott Laboratories?

Abbott Laboratories currently has 4 hold ratings, 17 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ABT.

What other companies compete with Abbott Laboratories?

Other companies that are similar to Abbott Laboratories include DexCom, Intuitive Surgical, Tesla, AbbVie and Boston Scientific. Learn More about companies similar to Abbott Laboratories.

How do I contact Abbott Laboratories' investor relations team?

Abbott Laboratories' physical mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker's listed phone number is (224) 667-6100. The official website for Abbott Laboratories is www.abbott.com. Learn More about contacing Abbott Laboratories investor relations.